A 24-week, multicenter, exploratory, two arm study to assess the effect of Dimethyl fumarate on Immune-Modulatory Action on T cells in patients with relapsing remitting Multiple Sclerosis

Trial Profile

A 24-week, multicenter, exploratory, two arm study to assess the effect of Dimethyl fumarate on Immune-Modulatory Action on T cells in patients with relapsing remitting Multiple Sclerosis

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 17 Jul 2017

At a glance

  • Drugs Dimethyl fumarate (Primary)
  • Indications Multiple sclerosis
  • Focus Therapeutic Use
  • Acronyms DIMAT-MS
  • Most Recent Events

    • 10 Jul 2017 Planned End Date changed from 1 Nov 2017 to 1 Sep 2018.
    • 10 Jul 2017 Planned primary completion date changed from 1 Nov 2016 to 1 Mar 2018.
    • 10 Jul 2017 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top